Aptamer and its therapeutic applications for age-related macular degeneration
10.3760/cma.j.issn.1005-1015.2017.04.028
- VernacularTitle:适配体及其在老年性黄斑变性治疗中的应用现状
- Author:
Jianmin LU
;
Xiaojing SUN
;
Xiang MA
- Keywords:
Macular degeneration/therapy;
Aptamers,nucleotide/therapeutic use;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2017;33(4):427-431
- CountryChina
- Language:Chinese
-
Abstract:
Vascular endothelial growth factor (VEGF),platelet derived growth factor (PDGF) and complements play key roles in the pathogenesis of age-related macular degeneration (AMD).Pegaptanib,the first therapeutic aptamer against VEGF165,has been approved by the Food and Drug Administration (FDA) of US for the treatment of exudative AMD.Another two aptamers El0030 and ARC1905,each target PDGF-B and complement C5 respectively,are undergoing clinical trials.Recent trends to treat AMD are combined therapies targeting multiple key molecules in the pathogenesis of AMD;aptamers against multiple targets may become the preferred drug for AMD.
